Geliga Ointment
NDC 60954-003
Product Information
Geliga (menthol, methyl salicylate) is a OTC MONOGRAPH DRUG-approved product labeled by Pt. Eagle Indo Pharma. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a ointment for topical administration. This product entry covers the primary NDC 60954-003 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 60954-003?
What are the uses of this product?
What are Active Ingredients of this product?
- MENTHOL 13.5 g/100g - A monoterpene cyclohexanol produced from mint oils.
- METHYL SALICYLATE 29.95 g/100g - used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- METHYL SALICYLATE (UNII: LAV5U5022Y)
- SALICYLIC ACID (UNII: O414PZ4LPZ) (Active Moiety)
- MENTHOL (UNII: L7T10EIP3A)
- MENTHOL (UNII: L7T10EIP3A) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WHITE PETROLATUM (UNII: B6E5W8RQJ4)
- PARAFFIN (UNII: I9O0E3H2ZE)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2642205 - menthol 13.5 % / methyl salicylate 29.95 % Topical Ointment
- RxCUI: 2642205 - menthol 0.135 MG/MG / methyl salicylate 0.3 MG/MG Topical Ointment
- RxCUI: 2642205 - menthol 13.5 % / methyl salicylate 30 % Topical Ointment
* Please review the full disclaimer at the bottom of this page.